IP Library Granted Patent US 10,413,508
Granted Patent B2
US 10,413,508 · App. 15/546,205 · Granted Sep 17, 2019

Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,413,508
App. No.
15/546,205
Granted
Sep 17, 2019
Kind
B2
Abstract

An improved process for producing an oil-in-water emulsion to deliver a substantially water insoluble active pharmaceutical ingredient includes creating a microemulsion containing such ingredient in the oil phase of the emulsion by mixing an aqueous phase including non-ionic surfactant, polyol, and water, wherein the weight ratio of the surfactant to polyol to water is between 10:20:70 and 1:1:1, to generate a mixture, with an oil phase comprising a substantially water insoluble active pharmaceutical ingredient and a long-chain triglyceride; circulating the said mixture through a homogenizer at a temperature from 20° C. to 60° C. to generate a coarse emulsion; passing the coarse emulsion through a microfluidizer at a pressure of from 70 MPa to 150 MPa at least once to produce an oil-in-water microemulsion; and, optionally, filtering the microemulsion through a 0.2 μm filter and/or mixing the microemulsion with a polymeric stabilizer.

Claims (24)

1. A method of preparing a stable oil-in-water microemulsion, comprising the steps of:

(a) mixing an aqueous phase comprising a non-ionic surfactant, a polyol, and water to solubilize the surfactant and polyol in the aqueous phase, wherein the weight ratio of the surfactant to polyol to water is between 10:20:70 and 1:1:1, with an oil phase comprising a substantially water insoluble active pharmaceutical ingredient and a long-chain triglyceride to generate a mixture, wherein the weight ratio of the oil phase to the aqueous phase is between about 0.01:1 and 1:1;

(b) passing the mixture produced in step (a) at least once through a homogenizer at a temperature of from about 20° C. to about 50° C. to generate a coarse emulsion; and

(c) passing the coarse emulsion at least once through a microfluidizer at a pressure of from about 70 MPa to about 150 MPa to produce an oil-in-water microemulsion having a mean oil particle droplet size of between about 50 nm and 300 nm.

2. The method of claim 1 , wherein the non-ionic surfactant is a polyoxyethylene derivative of a sorbitan ester.

3. The method of claim 1 , wherein the non-ionic surfactant is polysorbate 80.

4. The method of claim 1 , wherein the polyol is a sugar alcohol.

5. The method of claim 1 , wherein the polyol is a glycerol.

6. The method of claim 1 , wherein the weight ratio of the oil phase to the aqueous phase is from about 0.01:1 to about 0.1:1.

7. The method of claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of: paclitaxel, docetaxel, ortataxel taxane, and epothilone.

8. The method of claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of: geladanamycin, rapamycin, vancomycin, and bleomycin.

9. The method of claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of: thyroid hormone and melatonin.

10. The method of claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of: cyclosporine, tacrolimus, and mycophenolic acid.

11. The method of claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of: amiodarone, corticosteroid, propofol.

12. The method of claim 1 , wherein the active pharmaceutical ingredient is selected from radiocontrast agents.

13. The method of claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of: camptothecin, colchicine, amphotericin, cyclosporine, mycophenolic acid, ifosfamide, vinorelbine, gemcitabine and thiotepa.

14. The method of claim 1 , wherein the active pharmaceutical ingredient is cyclosporine.

15. The method of claim 1 , further comprising the step of

(d) filtering the microemulsion through a 0.2 μm filter.

16. The method of claim 15 , further comprising the step of

(e) mixing the microemulsion with a polymeric stabilizer after the filtration step (d).

17. The method of claim 16 , wherein the polymeric stabilizer is selected from the group consisting of: polyvinyl alcohol, polyvinyl acetal, polyvinylpyrrolidone, and polysaccharide.

18. An oil-in-water emulsion for delivering a substantially water insoluble active pharmaceutical ingredient produced by the method of claim 1 .

19. The method of claim 1 , wherein the pressure in step (c) is from about 125 MPa to about 150 MPa.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: R.P. SCHERER TECHNOLOGIES, LLC
To: WOLVERINE BIOSCIENCES, LLC
Reel/Frame 059566/0909 →
MERGER Recorded Apr 19, 2021
From: WOLVERINE BIOSCIENCES, LLC
To: WOODSTOCK STERILE SOLUTIONS, INC.
Reel/Frame 055955/0975 →
PATENT SECURITY AGREEMENT Recorded Apr 9, 2021
From: WOLVERINE BIOSCIENCES, LLC
To: CERBERUS BUSINESS FINANCE AGENCY, LLC, AS COLLATERAL AGENT
Reel/Frame 055886/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2021
From: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT PHARMA SOLUTIONS, INC.
To: WOLVERINE BIOSCIENCES, LLC
Reel/Frame 055821/0051 →
PATENT SECURITY AGREEMENT Recorded Mar 31, 2021
From: CATALENT USA WOODSTOCK, INC.
To: CERBERUS BUSINESS FINANCE AGENCY, LLC, AS THE COLLATERAL AGENT
Reel/Frame 055778/0019 →